TNFRSF9 and gastric cancer: Sanmamed et al. administered immunodeficient mice with gastric cancer patient lymphocytes, then administered mice with transplanted gastric cancer tissue, and then with nivolumab (inhibitor of PD-1) and urelumab (anti-CD137 agonist).